Companion Diagnostics Market Size 2024-2028

The companion diagnostics market is forecast to expand by USD 28.98 billion at a CAGR of 36.5% between 2023 and 2028. The market is being driven by the rising adoption of precision medicine, increased industry collaborations, and growing investments in the life sciences sector. Companies are adapting their strategies to meet consumer demand for innovative, efficient, and cost-effective diagnostic solutions, particularly in oncology, neurological diseases, and rare diseases. This surge is fostering the need for personalized treatments tailored to genetic makeups, improving therapy choices, and advancing disease treatment methodologies.

For more details about the industry, get the PDF sample report for free

Companion Diagnostics Market Segmentation

The Companion Diagnostics market report provides a comprehensive analysis of the market segments, including region-wise estimates and forecasts for 2024-2028, with historical data from 2018-2022.

By End-user

• Life science
• Health centers
• Others

By Indication

• Oncology
• Neurology
• Others

By Geography

• North America
  • US
• Europe
  • Germany
  • UK
  • France
• Asia
  • Japan
• Rest of World (ROW)

Get more details by ordering the complete report

Market Dynamics: Drivers, Trends, and Challenges

Drivers

1. Personalized Medicine: The increasing emphasis on personalized medicine, which tailors treatments to individual patients based on genetic data, is a key driver of market growth. This trend is particularly significant in oncology, where genetic sequencing and biomarkers play a crucial role in selecting therapies.

2. Growing Demand for Targeted Therapies: Advancements in immunotherapies and the need for targeted drug development in oncology, cardiovascular diseases, and neurological disorders are fueling the companion diagnostics market.

Trends

1. Rising Incidence of Cancer: The growing number of cancer cases in the US, especially breast and cervical cancers, is accelerating the demand for companion diagnostics. Approximately 250,000 breast cancer cases are diagnosed annually, making personalized treatment approaches critical.

2. Technological Advancements: The use of next-generation sequencing (NGS), immunohistochemistry (IHC), and cutting-edge sequencing technologies is expanding the scope of companion diagnostics in various therapeutic areas such as oncology, cardiovascular diseases, and neurological disorders.

Challenges

1. Limited Sustainability of Smaller Vendors: The market faces challenges regarding the sustainability of smaller vendors, who struggle to maintain competitiveness against larger, more established companies investing heavily in R&D.

Key Players

• Abbott Laboratories
• Abnova Corp.
• Agilent Technologies Inc.
• Amoy Diagnostics Co. Ltd.
• ARUP Laboratories
• Bayer AG
• BioGenex Laboratories Inc.
• bioMerieux SA
• F. Hoffmann La Roche Ltd.
• Guardant Health Inc.
• Illumina Inc.
• Invivoscribe Inc.
• Liquid Biotech USA Inc.
• Myriad Genetics Inc.
• NG Biotech
• QIAGEN NV
• Quest Diagnostics Inc.
• Siemens AG
• Sysmex Corp.
• Thermo Fisher Scientific Inc.

Recent Developments and News

• January 2025: Roche launched a new companion diagnostic test to help identify patients who will benefit from targeted therapies in oncology. This test uses genetic profiling to guide treatment decisions for lung cancer.

• December 2024: Thermo Fisher Scientific partnered with BioTherapies to co-develop a companion diagnostic for a new immuno-oncology drug. This collaboration aims to identify patients most likely to respond to the treatment.

• November 2024: Abbott acquired OncoDetect, a companion diagnostics company, to expand its oncology testing portfolio, enhancing cancer treatment precision.

• October 2024: QIAGEN launched a new companion diagnostic kit designed to identify patients with genetic mutations in breast cancer, enabling clinicians to match treatments to genetic profiles.